Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|3|270-272

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.3, 2015-03, pp. : 270-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 2050-2051

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 2050-2051

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

By  

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors

By Manrique Arechavaleta Gonzalo   Scholl Vanesa   Pérez Verónica   Bittencourt Roberta   Moellmann Arthur   Hassan Rocio   Seuánez Héctor   Dobbin Jane   Martinez Lem   Renault Ilana   Uriarte Rosario  

Clinical and Experimental Medicine, Vol. 11, Iss. 1, 2011-03 ,pp. : 55-59

Springer Publishing Company

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite